Detalhe da pesquisa
1.
Ribociclib plus Endocrine Therapy in Early Breast Cancer.
N Engl J Med
; 390(12): 1080-1091, 2024 Mar 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38507751
2.
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
N Engl J Med
; 386(6): 556-567, 2022 02 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35139274
3.
Radiotherapy statements of the 18th St. Gallen International Breast Cancer Consensus Conference-a German expert perspective.
Strahlenther Onkol
; 200(6): 461-467, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38393398
4.
Pembrolizumab for Early Triple-Negative Breast Cancer.
N Engl J Med
; 382(9): 810-821, 2020 02 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-32101663
5.
Return of individual genomic research results within the PRAEGNANT multicenter registry study.
Breast Cancer Res Treat
; 197(2): 355-368, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36409394
6.
Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast Cancer.
J Natl Compr Canc Netw
; 21(1): 33-41.e16, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36634607
7.
Current trends in diagnostic and therapeutic management of the axilla in breast cancer patients receiving neoadjuvant therapy: results of the German-wide NOGGO MONITOR 24 survey.
Arch Gynecol Obstet
; 307(5): 1547-1556, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36214890
8.
Th2/Th17 cell associated cytokines found in seroma fluids after breast cancer surgery.
Arch Gynecol Obstet
; 308(5): 1621-1627, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37243864
9.
Outcomes of patients with small and node-negative HER2-positive early breast cancer treated with adjuvant chemotherapy and anti-HER2 therapy-a sub-analysis of the ALTTO study.
Br J Cancer
; 127(10): 1799-1807, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36050448
10.
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
N Engl J Med
; 380(7): 617-628, 2019 02 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-30516102
11.
Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials.
Lancet Oncol
; 22(8): 1151-1161, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34252375
12.
Local and regional therapy considerations after preoperative therapy in patients with breast cancer.
Curr Opin Obstet Gynecol
; 33(1): 59-63, 2021 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33122576
13.
Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancer.
Cancer
; 126(13): 3132-3139, 2020 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32286687
14.
Efficacy and safety of tailored and dose-dense adjuvant chemotherapy and trastuzumab for resected HER2-positive breast cancer: Results from the phase 3 PANTHER trial.
Cancer
; 126(6): 1175-1182, 2020 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31851385
15.
Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany.
BMC Cancer
; 20(1): 1091, 2020 Nov 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33176725
16.
Evaluation of Pathologic Complete Response as a Surrogate for Long-Term Survival Outcomes in Triple-Negative Breast Cancer.
J Natl Compr Canc Netw
; 18(8): 1096-1104, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32755985
17.
Neutropenic complications in the PANTHER phase III study of adjuvant tailored dose-dense chemotherapy in early breast cancer.
Acta Oncol
; 59(1): 75-81, 2020 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-31583943
18.
Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy.
Int J Mol Sci
; 21(4)2020 Feb 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-32085669
19.
Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto.
Breast Cancer Res
; 21(1): 60, 2019 05 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31077239
20.
Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial.
Int J Cancer
; 145(3): 857-868, 2019 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30694523